UFP Technologies (UFPT) outlined its growth strategy at the 17th Annual Midwest IDEAS Conference on August 26, 2026, emphasizing scale and acquisitions to expand its position in the outsourced medical device manufacturing sector.
The company, based in Newburyport, Massachusetts, reported a market capitalization of approximately $2.5 billion and trailing twelve-month revenue of $631.6 million, with diluted earnings per share of $9.25 over the same period. UFP’s stock closed at $304.57 on August 26, up 0.12%, reflecting a year-to-date gain of 37% and a six-month increase of 41%. Key financial targets include a blended annual growth rate of 12% to 18% over the next three to five years, alongside gross margin expansion to 28%-31% and adjusted operating margin growth to 17%-20%.
CEO Mitch Roch described UFP as a "picks and shovels" provider for the medical device industry, operating in a fragmented $100 billion outsourced manufacturing market that is expanding at roughly 10% annually. UFP currently holds less than 1% market share, according to management. Roch highlighted the company’s long-term customer relationships, noting that programs typically span a decade or more, supported by a global manufacturing footprint across six locations: the U.S., Puerto Rico, Ireland, Mexico, Costa Rica, and the Dominican Republic.
The company’s pipeline includes 5 to 10 acquisition opportunities under review, with target EBITDA ranging from $5 million to $30 million per deal. CFO Ron Lataille emphasized disciplined inventory management, stating that finished goods growth reflects confirmed orders rather than speculative builds. UFP employs over 5,000 team members and serves primary markets including robotic-assisted surgery, cardiovascular devices, orthopedics, and wound care, with secondary exposure in endoscopy, imaging, and in vitro diagnostics.
Management also noted operational considerations, such as a two-week manufacturing shutdown in the Dominican Republic during late December, which requires strategic inventory planning.
